Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controllled, phase 3 study

the RADIANT-2 study group, Matti Välimäki

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalLancet
Volume378
Pages (from-to)2005-2012
ISSN0140-6736
Publication statusPublished - 2011
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3121 Internal medicine

Cite this